NASDAQ:IRD Opus Genetics 5/15/2025 Earnings Report $1.02 +0.07 (+7.37%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.02 +0.00 (+0.49%) As of 05/16/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Opus Genetics EPS ResultsActual EPS-$0.32Consensus EPS -$0.34Beat/MissBeat by +$0.02One Year Ago EPSN/AOpus Genetics Revenue ResultsActual Revenue$4.30 millionExpected Revenue$4.00 millionBeat/MissBeat by +$302.00 thousandYoY Revenue GrowthN/AOpus Genetics Announcement DetailsQuarterDate5/15/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Opus Genetics Earnings HeadlinesOpus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate UpdateMay 15 at 8:00 AM | globenewswire.comOpus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025May 13, 2025 | nasdaq.comShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.May 18, 2025 | Timothy Sykes (Ad)Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in MayMay 12, 2025 | globenewswire.comOpus Genetics (IRD) to Release Quarterly Earnings on FridayMay 8, 2025 | americanbankingnews.comOpus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy CandidateMay 6, 2025 | globenewswire.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds Upcoming Earnings PDD (5/20/2025)Palo Alto Networks (5/20/2025)Synopsys (5/20/2025)Home Depot (5/20/2025)Mitsubishi UFJ Financial Group (5/21/2025)Sumitomo Mitsui Financial Group (5/21/2025)Medtronic (5/21/2025)TJX Companies (5/21/2025)Snowflake (5/21/2025)Lowe's Companies (5/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
